Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

d-Alpha-Tocopherol · LPCN 1144

Small molecule · Inhibitor · developed by Lipocine

Phase 2 Most advanced trial (none active)
LPCN Developer
1 Registered trials

What is d-Alpha-Tocopherol?

d-Alpha-Tocopherol is a naturally occurring form of vitamin E with antioxidant activity as a peroxyl radical scavenger. It also noncompetitively inhibits cyclooxygenase activity and suppresses VEGF gene transcription. It is studied in nonalcoholic steatohepatitis, where it is given together with testosterone undecanoate in the LPCN 1144 formulation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LPCN 1144
Drug type
Small molecule
Mechanism
Inhibitor
Pathways
angiogenesis, prostaglandin production, Vascular endothelial growth factor (VEGF) gene transcription
Therapy area
Gastroenterology
Developer
Lipocine Inc. (LPCN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04134091 Phase 2 Nonalcoholic Steatohepatitis (NASH) Completed LPCN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Nonalcoholic Steatohepatitis (NASH)

More from Lipocine

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LPCN page.

Follow LPCN, the company behind d-Alpha-Tocopherol

See LPCN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LPCN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.